Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis.

Julien Damart,Georgios Filippou,Mariano Andrès,Edoardo Cipolletta,Silvia Sirotti, Davide Carboni,Emilio Filippucci,Pilar Diez,Abhishek Abhishek,Augustin Latourte,Hang-Korng Ea,Sébastien Ottaviani,Jean-Guillaume Letarouilly,Renaud Desbarbieux,Sahara Graf,Laurène Norberciak,Pascal Richette,Tristan Pascart

Rheumatology (Oxford, England)（2023）

引用 0|浏览0

暂无评分

摘要

Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra.

查看译文

关键词

calcium pyrophosphate deposition,crystal arthritis,colchicine,MTX,tocilizumab,anakinra

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要